214390.KS
Kyongbo Pharmaceutical Co., Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 5,420.00
−2.87%Year over year
Reported trailing growth
- Revenue
- +14.8%
- EBITDA
- -16.2%
- EBIT
- -69.6%
- EPS
- +1166.9%
- Free cash flow
- -99.6%
- Operating cash flow
- +1033.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.4%
- EBITDA
- +9.4%
- EBIT
- +36.2%
- Net income
- -33.2%
- EPS
- -33.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026